Business
Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
GAITHERSBURG, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an abstract on
About this update from Altimmune, Inc.
[{"type":"text","content":"GAITHERSBURG, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an abstract on pemvidutide in subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease1 will be presented at the NASH-TAG Conference, which will be held in Park City, UT on January 4-6, 2024. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH2. Details for the presentation are as follows: Title:Pemvidutide-Induced Liver Fat Reduction in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease Correlates with Improvements in Non-Invasive Markers of Inflammation and Fibrosis: Results of a 24-week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (abstract #51)Authors:Stephen A. Harrison, Shaheen Tomah, John J. Suschak, Jonathan Kasper, M. Scot Roberts, M. Scott Harris, Sarah K. BrowneDate:Saturday, January 6, 2024 A copy of the abstract will be accessible on the Events section of the Altimmune website. 1previously termed Non-Alcoholic Fatty Liver Disease2 previously termed NASH About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and MASH, formerly known as NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter Investor Contact:Rich EisenstadtChief Financial OfficerPhone: [email protected] Media Contact:Danielle CanteyEvoke CanalePhone: [email protected] \nSource: Altimmune, Inc","length":6094,"tagName":"div"}]